Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

NCT ID: NCT01462266

Last Updated: 2018-08-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 660 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-01-13
• Study Completion Date: 2013-06-07

Brief Summary

The purpose of this study is to examine the insulin-sparing effect of sitagliptin 100 mg once-daily compared with placebo over 24 weeks in participants with type 2 diabetes mellitus who have inadequate glycemic control on insulin alone or in combination with metformin. The primary hypothesis of this study is that after 24 weeks, sitagliptin reduces the dose of insulin relative to placebo.

Conditions

Type 2 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Sitagliptin

Sitagliptin 100 mg once daily

Group Type: EXPERIMENTAL

Sitagliptin

Intervention Type: DRUG

Sitagliptin 100 mg tablet once daily for 24 weeks

Insulin Glargine

Intervention Type: BIOLOGICAL

Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.

Metformin

Intervention Type: DRUG

Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.

Placebo

Placebo to sitagliptin once daily

Group Type: PLACEBO_COMPARATOR

Comparator: Placebo

Intervention Type: DRUG

Placebo to sitagliptin once daily for 24 weeks

Insulin Glargine

Intervention Type: BIOLOGICAL

Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.

Metformin

Intervention Type: DRUG

Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.

Interventions

Sitagliptin

Sitagliptin 100 mg tablet once daily for 24 weeks

Intervention Type: DRUG

Comparator: Placebo

Placebo to sitagliptin once daily for 24 weeks

Intervention Type: DRUG

Insulin Glargine

Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.

Intervention Type: BIOLOGICAL

Metformin

Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.

Intervention Type: DRUG

Other Intervention Names

Januvia; Glucophage

Eligibility Criteria

Inclusion Criteria

• has type 2 diabetes mellitus
• has one of the following criteria:

• diagnosed with diabetes after age 40 years and insulin therapy was initiated at least 3 years following diagnosis
• if diagnosed with diabetes under age 40 years or insulin started earlier than 3 years after diagnosis, has a fasting C-peptide greater than 0.7 ng/mL
• must be at least 18 years of age and less than or equal to 80 years of age (for participants in India: must be at least 18 years of age and less than or equal to 65 years of age)
• on a stable regimen of insulin for at least 10 weeks with or without metformin (at least 1500 mg/day) and/or sulfonylurea for at least 10 weeks
• is highly unlikely to become pregnant (not of reproductive potential or agrees to remain abstinent or use (or have their partner use) an acceptable method of birth control during the study and for 14 days after the last dose of study medication

Exclusion Criteria

• has been treated with a dipeptidyl peptidase IV (DPP-4) inhibitor, a thiazolidinedione (TZD), or a glucagon-like peptide-1 (GLP-1) mimetic or analogue, within the past 12 weeks
• currently on treatment with daily use (one or more injections per day) of a

pre-prandial short-acting or rapid-acting insulin alone or as part of a basal/bolus insulin regimen

• has symptomatic hyperglycemia that requires immediate initiation, adjustment, or addition of antihyperglycemic therapy
• has a history of 2 or more episodes of hypoglycemia resulting in seizure,

coma, or loss of consciousness, - or - has had recurrent (≥3 times per week) episodes of hypoglycemia over the past 8 weeks

• has a history of ketoacidosis
• is not appropriate for or does not agree to target a fasting glucose of 72-100 mg/dL [4.0-5.6 mmol/L]
• is on or likely to require treatment with corticosteroids
• has undergone a surgical procedure within 4 weeks or has planned major surgery during the study
• is currently being treated for hyperthyroidism or is on thyroid hormone

therapy and has not been on a stable dose for at least 6 weeks

• has a history of active liver disease (other than non-alcoholic hepatic

steatosis)

• has had new or worsening signs or symptoms of coronary heart disease or

congestive heart failure within the past 3 months, or has any of the following

disorders within the past 3 months:

• acute coronary syndrome
• coronary artery intervention
• stroke or transient ischemic neurological disorder

• has a systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure greater than 90 mm Hg
• has human immunodeficiency virus (HIV)
• has severe peripheral vascular disease
• has a clinically important hematological disorder
• has a history of malignancy that is less than 5 years from study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
• has a positive urine pregnancy test
• is pregnant or breast-feeding, or is expecting to conceive or donate eggs

during the study

• a user of recreational or illicit drugs or has had a recent history of drug abuse

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

References

Mathieu C, Shankar RR, Lorber D, Umpierrez G, Wu F, Xu L, Golm GT, Latham M, Kaufman KD, Engel SS. A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. Diabetes Ther. 2015 Jun;6(2):127-42. doi: 10.1007/s13300-015-0105-3. Epub 2015 Mar 28.

Reference Type: RESULT

PMID: 25820927 (View on PubMed)

Study Documents

Document Type: CSR Synopsis

View Document

Other Identifiers

0431-260

Identifier Type: -

Identifier Source: org_study_id